Opus Genetics, Inc. (IRD) Balance Sheet
IRD balance sheet, 2025
December 31, 2025 · U.S. dollars$50.2M assets = $34.9M liabilities + $15.3M equity
Both columns are drawn to the same scale: what IRD owns equals what it owes plus shareholders’ equity. Hover a block for its value.
IRD financial health
Descriptive bands, not a rating. Fiscal 2025.
IRD balance sheet trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $1.8M2019 | $50.2M2025 | +74.4%/yr | |
| Total liabilities | $9.3M2019 | $34.9M2025 | +24.6%/yr | |
| Shareholders’ equity | −$7.6M2019 | $15.3M2025 | — | |
| Cash & short-term investments | $1.5M2019 | $45.1M2025 | +75.6%/yr | |
| Total debt | $5.7M2019 | $1.1M2025 | −23.6%/yr | |
| Net cash (debt) | −$4.1M2019 | $44.0M2025 | +$48.1M | |
| Working capital | −$7.6M2019 | $42.3M2025 | +$49.8M | |
| Book value per share | $2.242022 | $0.252024 | −66.5%/yr | |
| Current ratio | 0.192019 | 6.432025 | +6.24 | |
| Debt / equity | 0.022021 | 0.072025 | +0.05 | |
| Shares outstanding | 20.6M2022 | 26.7M2024 | +13.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
IRD assets
IRD liabilities and equity
IRD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
IRD balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $45.1M | $30.3M | $50.5M | $42.7M | $24.8M | $16.4M | $1.5M |
| Cash & equivalents | $45.1M | $30.3M | $50.5M | $42.6M | $24.5M | $16.4M | $1.5M |
| Short-term investments | $0 | $2,000 | $15,000 | $49,000 | $219,000 | $0 | — |
| Receivables | $3.2M | $5.8M | $2.3M | $4.8M | $0 | $0 | $125,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.8M | $515,000 | $1.1M | $1.5M | $1.3M | $1.3M | $100,000 |
| Total current assets | $50.0M | $36.6M | $53.9M | $49.0M | $26.1M | $17.7M | $1.8M |
| Property, plant & equipment (net) | $199,000 | $252,000 | $0 | $6,000 | $10,000 | $14,000 | $22,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M | $17.7M | $1.8M |
| Liabilities | |||||||
| Accounts payable | $3.3M | $3.1M | $2.2M | $1.1M | $1.6M | $1.2M | $342,000 |
| Short-term debt | — | — | — | — | $538,000 | — | $5.7M |
| Total current liabilities | $7.8M | $11.3M | $4.0M | $2.8M | $3.9M | $3.2M | $9.3M |
| Long-term debt | $1.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $26.0M | $18.8M | $0 | $635,999 | $0 | $28.0M | $0 |
| Total liabilities | $34.9M | $30.1M | $4.0M | $2.8M | $3.9M | $31.1M | $9.3M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $7,000 | $3,000 | $2,000 | $2,000 | $2,000 | $1,000 | — |
| Retained earnings (deficit) | −$188.6M | −$139.0M | −$81.5M | −$71.5M | −$89.4M | −$32.7M | −$8.1M |
| Total shareholders' equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M | −$13.5M | −$7.6M |
| Key figures | |||||||
| Total debt | $1.1M | $18.8M | — | — | $538,000 | — | $5.7M |
| Net cash (debt) | $44.0M | $11.5M | — | — | $24.2M | — | −$4.1M |
| Working capital | $42.3M | $25.3M | $49.9M | $46.2M | $22.2M | $14.5M | −$7.6M |
| Tangible book value | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M | −$13.5M | −$7.6M |
| Book value per share | — | $0.25 | $2.31 | $2.24 | — | — | — |
| Shares outstanding | — | 26.7M | 21.6M | 20.6M | — | — | — |
| Current ratio | 6.43 | 3.24 | 13.35 | 17.79 | 6.76 | 5.55 | 0.19 |
| Quick ratio | 6.20 | 3.20 | 13.07 | 17.27 | 6.42 | 5.15 | 0.18 |
| Debt / equity | 0.07 | 2.80 | — | — | 0.02 | — | — |
| Equity / assets | 30.5% | 18.2% | 92.5% | 94.4% | 85.2% | −76.2% | −423.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $88.8M | $60.0M | $45.1M | $30.8M | $32.4M | $41.8M | $30.3M | $36.6M | $41.4M | $47.2M | $50.5M | $42.4M |
| Cash & equivalents | $88.8M | $60.0M | $45.1M | $30.8M | $32.4M | $41.8M | $30.3M | $36.6M | $41.4M | $47.2M | $50.5M | $42.4M |
| Short-term investments | — | — | $0 | $0 | $0 | $1,000 | $2,000 | $3,000 | $5,000 | $5,000 | $15,000 | $11,000 |
| Receivables | $1.5M | $2.7M | $3.2M | $4.3M | $4.6M | $4.8M | $5.8M | $3.3M | $2.3M | $3.1M | $2.3M | $11.3M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $2.4M | $3.9M | $1.8M | $815,000 | $1.4M | $1.4M | $515,000 | $429,000 | $1.1M | $1.6M | $1.1M | $484,000 |
| Total current assets | $92.7M | $66.6M | $50.0M | $35.9M | $38.4M | $47.9M | $36.6M | $40.4M | $44.8M | $51.8M | $53.9M | $54.2M |
| Property, plant & equipment (net) | $172,000 | $186,000 | $199,000 | $212,000 | $226,000 | $239,000 | $252,000 | $0 | $0 | $0 | $0 | $3,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $100,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $93.0M | $66.8M | $50.2M | $36.1M | $38.7M | $48.2M | $36.9M | $40.4M | $44.8M | $51.8M | $53.9M | $54.2M |
| Liabilities | ||||||||||||
| Accounts payable | $1.9M | $4.4M | $3.3M | $2.4M | $1.5M | $2.4M | $3.1M | $844,000 | $634,000 | $2.1M | $2.2M | $1.9M |
| Total current liabilities | $7.6M | $9.3M | $7.8M | $29.1M | $20.2M | $24.3M | $11.3M | $6.1M | $4.2M | $5.8M | $4.0M | $3.9M |
| Long-term debt | $36.2M | $1.2M | $1.1M | $1.1M | $1.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $62.1M | $102.1M | $26.0M | $0 | $0 | $18.8M | $18.8M | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $106.0M | $112.6M | $34.9M | $30.2M | $21.2M | $43.1M | $30.1M | $6.1M | $4.2M | $5.8M | $4.0M | $3.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $8,000 | $7,000 | $7,000 | $6,000 | $6,000 | $5,000 | $3,000 | $3,000 | $3,000 | $3,000 | $2,000 | $2,000 |
| Retained earnings (deficit) | −$262.2M | −$254.1M | −$188.6M | −$172.1M | −$154.6M | −$147.2M | −$139.0M | −$103.9M | −$96.3M | −$88.6M | −$81.5M | −$76.7M |
| Accumulated other comprehensive income | — | — | — | — | $0 | — | — | — | — | — | — | — |
| Total shareholders' equity | −$13.0M | −$45.8M | $15.3M | $6.0M | $17.5M | $5.1M | $6.7M | $34.3M | $40.6M | $46.1M | $49.9M | $50.3M |
| Key figures | ||||||||||||
| Total debt | $34.9M | $25.9M | $1.1M | $1.1M | $1.0M | $18.8M | $18.8M | — | — | — | — | — |
| Net cash (debt) | $53.9M | $34.0M | $44.0M | $29.7M | $31.4M | $22.9M | $11.5M | — | — | — | — | — |
| Working capital | $85.1M | $57.3M | $42.3M | $6.8M | $18.2M | $23.7M | $25.3M | $34.3M | $40.6M | $46.1M | $49.9M | $50.3M |
| Tangible book value | −$13.0M | −$45.8M | $15.3M | $6.0M | $17.5M | $5.1M | $6.7M | $34.3M | $40.6M | $46.1M | $49.9M | $50.3M |
| Book value per share | −$0.12 | — | — | $0.08 | $0.28 | $0.15 | $0.21 | $1.31 | $1.57 | $1.88 | $2.27 | $2.24 |
| Shares outstanding | 111.4M | — | — | 70.6M | 63.4M | 33.9M | 31.6M | 26.1M | 25.8M | 24.5M | 22.0M | 22.4M |
| Current ratio | 12.19 | 7.13 | 6.43 | 1.23 | 1.90 | 1.98 | 3.24 | 6.63 | 10.68 | 8.96 | 13.35 | 13.86 |
| Quick ratio | 11.87 | 6.71 | 6.20 | 1.21 | 1.83 | 1.92 | 3.20 | 6.56 | 10.41 | 8.69 | 13.07 | 13.74 |
| Debt / equity | — | — | 0.07 | 0.18 | 0.06 | 3.71 | 2.80 | — | — | — | — | — |
| Equity / assets | −14.0% | −68.6% | 30.5% | 16.5% | 45.2% | 10.5% | 18.2% | 84.9% | 90.6% | 88.8% | 92.5% | 92.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 12, 2026); data from EODHD.
IRD financial position
At the end of fiscal 2025 (December 31, 2025), Opus Genetics had total assets of $50.2 million (up 36.3% from a year earlier), total liabilities of $34.9 million and shareholders' equity of $15.3 million. It held $45.1 million in cash and short-term investments against $1.1 million of debt, a net cash position of $44.0 million. Its current ratio was 6.43. In the latest quarter (ended June 30, 2026) total assets were $93.0 million and equity -$13.0 million.
Related: IRD income statement, IRD cash flow statement, IRD key metrics. See the IRD stock overview for the latest quote and news.
IRD balance sheet FAQ
What are Opus Genetics's total assets?
Opus Genetics reported total assets of $50.2 million at the end of fiscal 2025 (December 31, 2025), compared with $36.9 million a year earlier.
How much debt does Opus Genetics have?
Opus Genetics had $1.1 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was 0.07.
How much cash does Opus Genetics have?
Opus Genetics held $45.1 million in cash and short-term investments at the end of fiscal 2025; with $1.1 million of debt that is net cash of $44.0 million.
What is Opus Genetics's book value?
Opus Genetics's shareholders' equity (book value) was $15.3 million at the end of fiscal 2025.
What is Opus Genetics's current ratio?
Opus Genetics had current assets of $50.0 million and current liabilities of $7.8 million, a current ratio of 6.43 (it can cover its short-term obligations).